{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:57Z","timestamp":1790803737337,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.09.019","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T10:57:47Z","timestamp":1731149867000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Elexacaftor\/tezacaftor\/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls"],"prefix":"10.1016","volume":"24","author":[{"given":"Suzanne","family":"Kroes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlou C.","family":"Bierlaagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-8575","authenticated-orcid":false,"given":"Juliet W.","family":"Lefferts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-2831","authenticated-orcid":false,"given":"Danya","family":"Muilwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1739-6046","authenticated-orcid":false,"given":"Carla","family":"Viscomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha D.A.","family":"Keijzer-Nieuwenhuijze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-6775","authenticated-orcid":false,"given":"Luca","family":"Cristiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Niem\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibo F.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-5672","authenticated-orcid":false,"given":"Renato","family":"Cutrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro G.","family":"Fiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-607X","authenticated-orcid":false,"given":"Vincenzina","family":"Lucidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis K.","family":"van der Ent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-3756","authenticated-orcid":false,"given":"Jeffrey M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-791X","authenticated-orcid":false,"given":"Federico","family":"Alghisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1493-9767","authenticated-orcid":false,"given":"Fabiana","family":"Ciciriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2024.09.019_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4922","key":"10.1016\/j.jcf.2024.09.019_bib0002","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jcf.2024.09.019_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.09.019_bib0004","first-page":"e16144","article-title":"A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.jcf.2024.09.019_bib0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.019_bib0006","doi-asserted-by":"crossref","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jcf.2024.09.019_bib0007","unstructured":"U.S. Food & Drug Administration. Highlights of prescribing information. Preprint at (2019)."},{"key":"10.1016\/j.jcf.2024.09.019_bib0008","unstructured":"ECFSPR 2021 Annual Data Report. doi:https:\/\/www.ecfs.eu\/sites\/default\/files\/Annual%20Report_2021_09Jun2023.pdf."},{"issue":"2","key":"10.1016\/j.jcf.2024.09.019_bib0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.0.CO;2-J","article-title":"Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The biomed CF mutation analysis consortium","volume":"10","author":"Estivill","year":"1997","journal-title":"Hum Mutat"},{"issue":"4 Suppl 2","key":"10.1016\/j.jcf.2024.09.019_bib0010","first-page":"1","article-title":"Italian cystic fibrosis registry (ICFR) report 2019\u20132020","volume":"46","author":"Campagna","year":"2022","journal-title":"Epidemiol Prev"},{"key":"10.1016\/j.jcf.2024.09.019_bib0011","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/MCP.0000000000000521","article-title":"Theratyping in cystic fibrosis","volume":"24","author":"Crawford","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2024.09.019_bib0012","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jcf.2019.06.010","article-title":"Theranostics by testing CFTR modulators in patient-derived materials: the current status and a proposal for subjects with rare CFTR mutations","volume":"18","author":"Amaral","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.019_bib0013","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"issue":"344","key":"10.1016\/j.jcf.2024.09.019_bib0014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2024.09.019_bib0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2024.09.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00508-2021","article-title":"Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression","volume":"60","author":"Muilwijk","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.09.019_bib0017","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jcf.2019.10.022","article-title":"Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations","volume":"19","author":"de Winter \u2013 de Groot","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.019_bib0018","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"issue":"19","key":"10.1016\/j.jcf.2024.09.019_bib0019","doi-asserted-by":"crossref","first-page":"14539","DOI":"10.3390\/ijms241914539","article-title":"CFTR function restoration upon elexacaftor\/tezacaftor\/ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.09.019_bib0020","doi-asserted-by":"crossref","unstructured":"Bihler, H. et al. In vitro modulator responsiveness of 655 CFTR variants found in people with CF. bioRxiv (2023).","DOI":"10.1101\/2023.07.07.548159"},{"issue":"1","key":"10.1016\/j.jcf.2024.09.019_bib0021","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"issue":"246","key":"10.1016\/j.jcf.2024.09.019_bib0022","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/scitranslmed.3008680","article-title":"Cystic fibrosis: potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.jcf.2024.09.019_bib0023","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1093\/hmg\/ddx367","article-title":"Mutation-specific downregulation of CFTR2 variants by gating potentiators","volume":"26","author":"Avramescu","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jcf.2024.09.019_bib0024","unstructured":"European Medicines Agency. Letter of support for forskolin-induced swelling (FIS) assay: biomarker for cystic fibrosis transmembrane conductance regulator protein (CFTR). (2023)."},{"issue":"6","key":"10.1016\/j.jcf.2024.09.019_bib0025","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.019_bib0026","doi-asserted-by":"crossref","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jcf.2024.09.019_bib0027","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.019_bib0028","article-title":"Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalized approach","author":"Spelier","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.09.019_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.04.014","article-title":"Repeatability and reproducibility of the forskolin-induced swelling (FIS) assay on intestinal organoids from people with cystic fibrosis","author":"Bierlaagh","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.09.019_bib0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/jpm12040632","article-title":"Theratyping of the rare CFTR variants E193K and R334W in rectal organoid-derived epithelial monolayers","volume":"12","author":"Ciciriello","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2024.09.019_bib0031","unstructured":"Labelbox Inc: the leading training data platform for data labeling. https:\/\/labelbox.com\/."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:11:27Z","timestamp":1738257087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324017879"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.019","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/tezacaftor\/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}